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Lipid membraneAminoglycosides are among the most potent antimicrobials to eradicate Pseudomonas aeruginosa. However,
the emergence of resistance has clearly led to a shortage of treatment options, especially for critically ill
patients. In the search for new antibiotics, we have synthesized derivatives of the small aminoglycoside,
neamine. The amphiphilic aminoglycoside 3′,4′,6-tri-2-naphtylmethylene neamine (3′,4′,6-tri-2NM nea-
mine) has appeared to be active against sensitive and resistant P. aeruginosa strains as well as Staphylococcus
aureus strains (Baussanne et al., 2010). To understand the molecular mechanism involved, we determined the
ability of 3′,4′,6-tri-2NM neamine to alter the protein synthesis and to interact with the bacterial membranes
of P. aeruginosa or models mimicking these membranes. Using atomic force microscopy, we observed a
decrease of P. aeruginosa cell thickness. In models of bacterial lipid membranes, we showed a lipid membrane
permeabilization in agreement with the deep insertion of 3′,4′,6-tri-2NM neamine within lipid bilayer as
predicted by modeling. This new amphiphilic aminoglycoside bound to lipopolysaccharides and induced
P. aeruginosamembrane depolarization. All these effects were compared to those obtained with neamine, the
disubstituted neamine derivative (3′,6-di-2NM neamine), conventional aminoglycosides (neomycin B and
gentamicin) as well as to compounds acting on lipid bilayers like colistin and chlorhexidine. All together, the
data showed that naphthylmethyl neamine derivatives target the membrane of P. aeruginosa. This should
offer promising prospects in the search for new antibacterials against drug- or biocide-resistant strains.32 2 764 73 73.
(M.-P. Mingeot-Leclercq).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Pseudomonas aeruginosa is ubiquitous in nature, colonizing soil,
industrial surfaces, humans and plants. This bacterium forms a large
proportion of the normal ﬂora found at nasal and pharyngeal mucosal
surfaces. In normal conditions, P. aeruginosa is harmless. However, if
the innate immune system is compromised or if the bacterium gains
access to submucosal tissues, P. aeruginosa can become a persistent
opportunistic pathogen. It represents a major cause of morbidity for
patients suffering of severe burns [1], cystic ﬁbrosis [2,3] or receiving
intensive care [4]. Taking the severity of the illness into account,
current guidelines recommend treatmentwith an aminoglycoside or a
ﬂuoroquinolone together with a beta-lactam. However, resistance to
such treatment is rapidly emerging resulting in worrisome resistance
rates and the appearance of multidrug-resistant Pseudomonas strains[5–8]. With the exception of doripenem, no new anti-pseudomonal
drugs have reached the market in recent years [9]. Therefore, it is
imperative to discover and develop novel anti-Pseudomonas drugs to
ﬁll a dangerous void in the antibacterial armamentarium of the
clinician.
Since aminoglycosides are the cornerstone in the treatment of
P. aeruginosa infections, the characterization of their actionmechanism
at the molecular level is critical to synthesize new derivatives active
against P. aeruginosa, including resistant strains, on a rational basis.
Crystallographic and nuclear magnetic resonance (NMR) studies have
shown that aminoglycosides target the double helix of the aminoacyl-
tRNA decoding site (RNA-A site) [10]. Neamine (Fig. 1), which is
prepared by methanolysis of neomycin B, is the main structural
element necessary for binding to the aminoacyl-tRNA decoding site
[11–13]. Therefore, it is a good candidate as a starting molecule in the
synthesis of new potential antibiotics. In naturally occurring amino-
glycosides like neomycin or paromomycin, the neamine-core adopts a
virtually identical positionwithin the binding site. Ring I is inserted into
the helix, where it covers guanine G1491, and binds to adenine A1408.
neamine: R1=R2=R3=R4=H
3’,6-di-2NM neamine: R1=R3=H, R2=R4=2NM
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Fig. 1. Structures of neamine, 3′,6-di-2NM neamine, 3′,4′,6-tri-2NM neamine.
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conserved U1406.U1495 pair as well as with guanine G1494 and a
phosphate group of adenine 1493 [14]. Upon binding, the neamine core
promotes the stabilization of two adenine bases (A1492 and A1493) of
the 16S RNA model in an extrahelical conformation thus increasing
their favorable interaction with tRNA. As a result, the ability of the
ribosomes to discriminate between cognate and non-cognate tRNA is
reduced,which in turn lowers the ﬁdelity of the translation process and
leads to the death of the bacterial cell.
In the last fewyears, several efforts havebeendone to synthesizenew
compounds with an enhanced afﬁnity for the RNA-A site [12,15–17].
Modiﬁed aminoglycosides have also been designed to induce a dual
action towards both protein synthesis and bacterial membranes. The
latter are targeted by the addition of lipophilic tails [18], linear lipidic
acyl groups [19,20], lipid chains and polyguanidinylated head groups
[21], hydrophobic residues in the form of polycarbamate and
polyethers [22] to the backbone of aminoglycoside. All the synthe-
sized derivatives have exhibited a strong activity against Gram-
positive bacteria includingmethicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE) but they have
failed to show activity against Gram-negative bacteria [18,19].
Recently, Baussanne et al. [23] have described the synthesis and the
antimicrobial property of neamine derivatives carrying hydrophobic
groups like naphthylmethylene. The naphthyl ring has been selected
since, as compared with an anthryl- or acridyl ring, it has a higher
selectivity for binding to polyA.polyU as an RNA model [24]. Very
interestingly, the 3′,4′,6-tri-2-naphthylmethylene (3′,4′,6-tri-2NM)
neamine derivative (Fig. 1) has shown antimicrobial activity
against P. aeruginosa including strains expressing efﬂux pumps or
inactivating enzymes [23]. It is also active against both sensitive
and resistant strains of Escherichia coli, Klebsiella pneumoniae and
Acinetobacter lwofﬁi, including strains expressing r-methylase against
which gentamicin, amikacin and tobramycin are totally inactive
(MICN128 μg/ml) [23]. Moreover, the 3′,4′,6-tri-2NM neamine has
shown a low MIC (2–4 μg/ml) against sensitive and resistant S. aureus
strains including MRSA and vancomyin-resistant S. aureus (VRSA)
strains while clinically used aminoglycosides like amikacin and
gentamicin are much less active [23]. This antimicrobial activity is in
strict contrast to that of the 3′,6-di-2-naphthylmethylene neamine
derivative (3′,6-di-2NM; Fig. 1), which is active against Gram-positive
bacteria but fails to eradicate Gram-negative strains. Remarkably, the
3′,4′,6-tri-2-quinolylmethylene neamine derivative (3′,4′,6-tri-2-QN),
which differs from the 3′,4′,6-tri-2NM derivative through the
replacement of one carbon atom by a nitrogen atom in each naphthyl
ring, has appeared to be completely inefﬁcient against Gram(+) and
Gram(−) bacteria [23].The strong activity of 3′,4′,6-tri-2NMneamine against P. aeruginosa
pushed us to further investigate the mechanism involved. We
therefore evaluated its ability to alter protein synthesis as well as to
interact with the bacterial membranes of P. aeruginosa or models
mimicking these membranes. All these effects were compared to
those obtained with neamine, the di-substituted neamine derivative
(3′,6-tri-2NM neamine), conventional aminoglycosides (neomycin B
and gentamicin) as well as to compounds acting on lipid bilayers. Two
compounds were selected in this respect, colistin (also called
polymyxin E and used as an anti-pseudomonal compound) [25–30]
and chlorhexidine (a broad-spectrum biocidal compound) [31,32].
To combine both fundamental studies with potential clinical
interest of the new amphiphilic aminoglycosides, the work will be
performed using both models of membranes as well as on entire
bacteria.
First, on entire bacteria, we took advantage of atomic force
microscopy (AFM) to investigate in situ the effect of 3′,4′,6-tri-2NM
neamine on surface nanostructure of bacteria. In parallel, we charac-
terized the ability of both 3′,6-di-2NM neamine and 3′,4′,6-tri-2NM
neamine to depolarize the cytoplasmic membrane of P. aeruginosa
using DiSC3(5). We also examined their relative binding toward
lipopolysaccharides (LPS) using a ﬂuorescence based displacement
assayusingBODIPY-TR cadaverine. Toobtain further informationon the
interactions of both derivatives with lipid membranes, we determined
their permeabilizing effect in models of bacterial lipid membranes
by following the release of calcein entrapped within liposomes.
Yet, we carried out molecular modeling of both compounds in
interaction with the major lipids found in cytoplasmic membranes of
P. aeruginosa. All our data suggest that the activity of 3′,4′,6-tri-2NM
neamine against P. aeruginosa is related to its ability to target lipid
membranes.
2. Materials and methods
2.1. Materials
P. aeruginosa [ATCC 27853 and Psa.F03 (PAZ505H8101)] and E. coli
(PAZ505H8101) were obtained from the Pasteur Institute (Brussels,
Belgium; Prof. R. Vanhoof). P. aeruginosa (PT629, PA22) was provided
by the Department of Bacteriology, University of Franche-Comte,
Faculty of Medicine (Besancon, France; Prof. P. Plésiat) and E. coli
(06AB003), by the Laboratory of Bacteriology, Cliniques Universitaires
UCL deMont-Godinne (Yvoir, Belgium; Prof. Y. Glupczynski). S. aureus
(ATCC 25923) and E. coli (25922) were provided by ATCC-LGC
(Middlesex, TW11 OLY, UK). MRSA and VRSA strains were obtained
from NARSA (Network on Antimicrobal Resistance in S. aureus) via
Euroﬁns Medinet Inc., Herndon, VA).
LPS E. coli (0111:B4) was supplied from Quadratech (Epsom,
Surrey, UK). Valinomycin was purchased from Calbiochem. Beef
heart cardiolipin (CL; Disodium Salt; purityN99%), 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG) sodium salt
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
(POPE) were purchased from Avanti Polar Lipids (Alabaster, AL,
USA) and used without further puriﬁcation. 3,3′ Dipropyl thiadicar-
bocyanine iodide (DiSC3(5)) and 5-(((4-(4,4-diﬂuoro-5-(2-thienyl)-
4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentyla-
mine, hydrochloride (BODIPY-TR-cadaverine) were obtained from
Molecular probes, Inc. (Eugene, OR). Neomycin B sulfate and calcein
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Calcein was
puriﬁed as described previously [33]. Brieﬂy, calcein was dissolved in
6 N NaOH and subjected to size-exclusion chromatography through a
SephadexR LH-20 column. The ﬁnal concentration of calcein solution
in 20 mM Tris–HCl was 73 mM with an osmolarity of 434 mOsm/kg
(measured by the freezing point technique, using a model 3C2
Advanced Cryomatic Osmometer [Advanced Instruments, Needham
Heights, MA]). Other reagents were purchased from E. Merck AG
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Organics (Illkirch, France).
2.2. 3′,6-di-2-naphthylmethylene neamine and 3′,4′,6-tri-2-
naphthylmethylene neamine synthesis
The 3′,6-di-2NM neamine and the 3′,4′,6-tri-2NM neamine were
synthesized in three steps from neamine according to our previous
reports (21% and 19% yields, respectively): (i) tritylation of the four
amine functions, (ii) alkylation with 2-bromomethylnaphthalene
in DMF/THF (1:9) after addition of NaH and (iii) deprotection in
TFA/anisole [23,34].
2.3. Minimal inhibitory concentration determination
The minimal inhibitory concentration (MIC) was deﬁned as the
lowest concentration of antibiotic that prevented visible growth after
incubation at 37 °C for 18–24 h. All strains were grown on TSA-agar
plates (BD Diagnostics, BD, Franklin Lakes, NJ) at 37 °C, overnight.
The MICs were determined by a geometric microdilution method
according to the recommendations of the CLSI norms (2007) for
P. aeruginosa [ATCC 27853 (WT), Psa.F03, PA22], E. coli [ATCC 25922
(WT), EcPAZ505H8101, Ec06AB003 (Arm)], and S. aureus strains
[ATCC 25923 (WT), ATCC 33592 HA-MRSA and VRSA VRS-2].
2.4. Luciferase inhibition translation
Inhibition of cell-free translation by the different compounds was
quantiﬁed by using E. coli S30 Extracts System for circular DNA with
the pBestluc™ plasmid (Promega, Leiden, NL) as previously described
[35] with modiﬁcations. Brieﬂy, 10 μl of S30 premix, 7.5 μl of S30
extract, 2.5 μl of complete amino acid mixture, 0.25 μg of pBestluc™
plasmid and 2 μl of tested compounds at different concentrations
were mixed in a total volume of 25 μl. Translation reactions were
performed at 37 °C for 60 min, cooled at 4 °C for 5 min and diluted
10-fold with phosphate-buffered saline (PBS) 1× containing 1% BSA.
The luminescence was measured immediately after adding 5 μl of
the diluted mixture to 25 μl of the Luciferase assay reagent (Promega,
Leiden, NL) with a Luminometer (Turner Designs TD 20/20 Lumin-
ometer). Data were normalized to untreated reaction mixture
assigned to 100%.
2.5. Atomic force microscopy
AFM images were recorded in PBS solution (10 mM Na3PO4,
150 mM NaCl, pH 7.4) at room temperature, using a Nanoscope V
multimode AFM (Veeco Metrology Group, Santa Barabara, CA, USA).
P. aeruginosa (ATCC 27853) was ﬁltered onto a porous polycarbon-
ate membrane (Millipore) with a pore size similar to the bacterial
cell size (0.6 μm). After ﬁltering a concentrated cell suspension,
the ﬁlter was gently rinsed with PBS, carefully cut (1×1 cm), and
attached to a steel sample puck (Veeco Metrology Group) using a
small piece of adhesive tape and the mounted sample was
transferred into the AFM liquid cell while avoiding dewetting.
The 3′,4′,6-tri-2NM neamine was injected into the AFM liquid cell at
0.5 MIC (4 μg/ml).
2.6. Cytoplasmic membrane depolarization assay
The cytoplasmic membrane depolarization activity of neamine
derivatives was determined using the membrane potential-sensitive
dye DiSC3(5) [36]. This probe is taken up by bacterial cells according
to the magnitude of the electrical gradient of the cytoplasmic
membrane and becomes concentrated in the cytoplasmic mem-
brane, where it self-quenches its own ﬂuorescence [36]. Any
compound that alters the permeability of the cytoplasmic mem-brane and thus induces depolarization will lead to the release of
DiSC3(5) and a consequent increase in ﬂuorescence. This assay,
which is widely applied to monitor the membrane potential and ion
permeability in a variety of cells including red blood cells [36,37],
Gram-positive [38] and -negative bacteria [39,40], does not measure
membrane destruction or an equivalent lethal event [40].
Brieﬂy, overnight cultures of P. aeruginosa (ATCC 27853) were
diluted in CA-MHB media and allowed to grow to the exponential
phase (OD620=0.5–0.7). Bacteria were collected by centrifugation,
washed 3 times with buffer (5 mM HEPES, pH 7.8) and resuspended
in the same buffer added with 0.2 mM EDTA to an OD620 of 0.05.
The cell suspension was incubated during 20 min at 37 °C under
shaking (150 rpm) with 0.4 μM DiSC3(5) and 0.1 M KCl until dye
uptake was maximal (after 20 min a stable reduction in ﬂuores-
cence due to ﬂuorescence quenching was observed). The desired
concentration of the test compound was then added; the ﬂuores-
cence was monitored under shaking (150 rpm) at 37 °C at an
excitation wavelength of 622 nm and an emission wavelength of
670 nm after 15 min (Perkin-Elmer Model LS55, Perkin Elmer Ltd.,
Beaconsﬁeld, UK). A blank with only cells and the dye was used
as background. We previously checked the absence of effect on
DiSC3(5) ﬂuorescence and MICs, of EDTA (0.2 mM) and KCl (0.1 M)
used to permeabilize the outer membrane to allow dye uptake
and equilibrate the cytoplasmic and external K+ concentrations,
respectively.
2.7. Binding afﬁnities to LPS
The BODIPY-TR-cadaverine displacement assay was previously
used to quantify the afﬁnities of binding of the test compounds to LPS
[41]. The ﬂuorescence of BODIPY-TR-cadaverine is quenched upon
binding to LPS, and the displacement of BODIPY-TR-cadaverine by the
test compounds results in dequenching of BODIPY-TR-cadaverine
ﬂuorescence. Polymyxin B, a peptide antibiotic known to bind and
neutralize LPS [42], served as the positive control. Imipenem and
meropenem, acting by inhibiting the synthesis of the peptidoglycan
layer of bacterial cell walls are used as negative controls. Stock
solutions of LPS (5 mg/ml) and BODIPY-TR-cadaverine (500 μM)were
prepared in Tris buffer (pH 7.4, 50 mM). 1 ml each of the LPS and
BODIPY-TR-cadaverine stocks was mixed and diluted in Tris buffer to
a ﬁnal volume of 100 ml, yielding ﬁnal concentrations of 50 μg/ml of
LPS and 5 μM BODIPY-TR-cadaverine. 40 μl of this BODIPY-TR-
cadaverine:LPS mixture was added to each well of the plate.
Fluorescence measurements were made at 25 °C on a SPECTRAmax
GEMINI XS Microplate Spectroﬂuorometer (Biocompare), using
Spectra Max Gemini XS software. The BODIPY-TR-cadaverine excita-
tion wavelength was 580 nm. Emission spectra were taken at 620 nm.
Emission and excitation monochromator bandpasses were setting at
5 nm.
2.8. Large unilamellar vesicles preparation
Large unilamellar vesicles (LUV), composed of lipids mimicking
the composition of lipid membranes of P. aeruginosa (Phosphatidyl-
ethanolamine [PE], Phosphatidylglycerol [PG] and Cardiolipin [CL])
[43,44], were prepared by extrusion.
Lipids (POPE, POPG, CL; molar ratio 60:21:11) were dissolved in
CHCl3:CH3OH (2:1, v/v) and mixed to obtain the desired composition
in a round ﬂask. The solvent was evaporated using a Rotavapor system
(model R-210, Buchi Labortechnik AG, Flawil, Switzerland). Dried
ﬁlms were maintained under reduced pressure overnight and
thereafter hydrated with puriﬁed calcein in 20 mM Tris 200 mM
NaCl, pH 7.4. LUV were obtained after 5 cycles of freeze/thawing and
10 cycles of extrusion in a 10 ml Thermobarrel Extruder (Lipex
Biomembranes, Vancouver, Canada) under a nitrogen pressure of 10
bars through two polycarbonate ﬁlters of 100 nm (Nucleopore, Costar
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cein was removed using minicolumn centrifugation. The size and
polydispersity of liposome suspensions were monitored by quasi-
elastic light scattering with a Zetasizer Nano SZ (Malvern Instruments,
Worcestershire, UK). Lipid concentration on the liposomal suspen-
sions was measured by phosphorous quantiﬁcation as previously
described [45].
2.9. Liposomal membrane permeability assay
Permeabilization of lipid membranes induced by drugs was
monitored by following the leakage of entrapped calcein within
liposomes. We monitored the increase in ﬂuorescence of the samples,
resulting from the dilution and release of self-quenching of this tracer
[46] as previously described [33].
2.10. Log P and log D determinations
MarvinSketch software [Marvin 5.1.3, 2010, ChemAxon (http://
www.chemaxon.com)] was used for drawing, displaying, and char-
acterizing chemical structures and substructures. The log P plug-in in
this software was used to calculate the octanol/water partition
coefﬁcient, which is used in QSAR analysis and rational drug design
as a measure of molecular hydrophobicity.
2.11. Molecular modeling and assembly of neamine derivatives
with lipids
The assembly of neamine derivatives with lipids was studied by
molecular modeling. The neamine derivative structures were ﬁrst
constructed using Hyperchem 7.0 (Hypercube, Inc). A preliminary
geometry optimization was made by the steepest descent method
using the MM+force ﬁeld. The structures were then submitted to a
systematic analysis structure tree applied on the most important
torsional angles of each molecule [47]. The most probable structure
was then kept for the next steps.
The interaction and insertion of the neamine derivatives within
lipids were calculated using two methods, the hypermatrix and the
impala method as described previously [48–50].
The Pexmethod [51] was used to analyze themolecular assemblies
and calculations are performed on a Linux station bi-xeon quad
core, using Z-Ultim software. Graphs were drawn using WinMGM
(Ab Initio technology, Obernai, France).
2.12. Statistical analysis
Statistical analysis was done with GraphPad Prism, version 4.03,
for Windows (GraphPad Prism Software, San Diego, CA) using an
ANOVA with a Tukey post hoc test.Table 1
MIC values (μg/ml) of the compounds used in this study on P. aeruginosa-, E. coli- and S. au
P. aeruginosa E. coli
ATCC
27853
Psa.F03
AAC6′-IIA
PA22 Overexpres
MexXY
ATCC
25922
PAZ505H
AAC6′-IB
Resistance
mechanism
None Enzymatic Efﬂux None Enzymat
Neamine N128 N128 N128 32 N128
3′,6-di-2NM
neamine
128 128 N128 64 64
3′,4′,6-tri-2NM
neamine
8 8 4 16 4
Neomycin B 64 N128 N128 2 4
Gentamicin 1 N128 4 b0.5-1 13. Results
3.1. Antimicrobial activity against sensitive and resistant Gram(−) and
Gram(+) bacteria
The antimicrobial activity against sensitive and resistant Gram-
negative and Gram-positive bacteria of the tri-substituted (3′,4′,6-tri-
2NM neamine), and the di-substituted (3′,6-di-2NM neamine)
derivatives, as well as parent compounds (neamine, neomycin B
and gentamicin) is shown in Table 1. We also determined the MICs of
colistin and chlorhexidine digluconate against P. aeruginosa (ATCC
27853). They were 1 μg/ml and 8 μg/ml, respectively.
The tri-substituted derivative has revealed an interesting activity
against P. aeruginosa ATCC 27853 (MIC 8 μg/ml) as well as against
strains expressing modifying enzyme (AAC-6′-IIA) or efﬂux pump
(MexXY) (MICs of 8 and 4 μg/ml, respectively). The di-substituted
derivative, as well as neomycin B and neamine, has appeared to be
inactive whatever the selected strains. Gentamicin is active against
P. aeruginosa ATCC 27853 and strain expressing efﬂux pump (MexXY)
with MICs of 1 and 4 μg/ml, respectively but lost all activity against
strain expressing modifying enzyme (AAC6′-IIA) (MICN128 μg/ml).
Moving on enterobacteriacea, the tri-substituted derivative has
shown MIC against E. coli ATCC 25922 of 16 μg/ml lower than MIC
obtained for neamine (32 μg/ml) but higher than MICs found
with neomycin B (2 μg/ml) and gentamicin (b0.5–1 μg/ml). MICs of
4 μg/ml have been measured against strains expressing modifying
enzyme (AAC6′-IB) or r-methylase, near those obtained with
neomycin B (MICs of 4 and 1 μg/ml, respectively). Gentamicin also
was found active against E. coli expressing AAC-6′-IB (MIC 1 μg/ml)
but unfortunately inactive against strain expressing methylase
activity (MICN64 μg/ml). The di-substituted derivative and neamine
have appeared to be inactive whatever the strains selected.
Against Gram-positivebacteria, in the presence of the tri-substituted
derivative (3′,4′,6-tri-2NM neamine), a MIC of 4 μg/ml has been
measured against S. aureus ATCC 25923 slightly higher than MICs
found for neomycinB (2 μg/ml) or for gentamicin (0.5 μg/ml). Again, the
tri-substituted derivative has a strong activity against resistant strains
withMICs values rangingbetween2 and 4 μg/ml forMRSA andVRSA for
whichneomycinB lost all activity (MICsN128 μg/ml). Gentamicin is also
inactive against VRSA with a MIC of 32 μg/ml but still had an activity
against MRSA (MIC 1–2 μg/ml). Neamine was inactive whatever the
selected strains and the di-substituted derivative is only moderately
active against Gram-positive bacteria (MICs=8–16 μg/ml).
These results clearly have pointed out the antimicrobial activity of
the 3′,4′,6-tri-2NM neamine against both Gram-positive and Gram-
negative strains, including sensitive and resistant bacteria.
3.2. Bacterial protein synthesis
Inhibition of protein synthesis is the well-known mechanism of
action of aminoglycoside antibiotics. Thus, we ﬁrst investigated thereus-sensitive and -resistant strains.
S. aureus
8101 06AB003 ATCC
25923
ATCC 33592
HA-MRSA
VRSA-VRS-2
ic 16S RNA
methylase (arm)
None Low afﬁnity of
target for methicillin
Low afﬁnity for
glycopeptides
32 32 N128 N128
N128 8 16 16
4 4 2 4
1 2 N128 N128
N64 0.5 1-2 32
Fig. 2. Effect of neamine derivatives (3′,4′,6-tri-2NM neamine, 3′,6-di-2NM neamine),
neamine, neomycin B, gentamicin, colistin and chlorhexidine on bacterial protein
synthesis. Chloramphenicol and tetracycline are selected for their known inhibitory
potency towards protein synthesis. Aztreonam is chosen for the absence of effect on
protein synthesis. Protein translation inhibition by the different compounds is
quantiﬁed in a coupled transcription/translation assay by using E. coli S30 extracts for
circular DNA with the pBESTluc plasmid. The luminescence is measured immediately
after the addition of luciferase assay reagent. The compounds are tested at equimolar
concentrations (10 μM; panel A) as well as at their MICs against P. aeruginosa 27853
(panel B) (neamine [128 μg/ml; 397.1 μM], 3′,6-di-2NM neamine [128 μg/ml;
212.4 μM], 3′,4′,6-tri-2NM neamine [8 μg/ml; 10.8 μM], neomycin B [64 μg/ml;
104.1 μM], gentamicin [1 μg/ml; 2.1 μM], colistin [1 μg/ml; 0.9 μM], chlorhexidine
[8 μg/ml; 8.9 μM], aztreonam [4 μg/ml; 9.2 μM], chloramphenicol [64 μg/ml; 198.1 μM],
tetracycline [16 μg/ml; 36.0 μM]). Panel C shows the effect of 3′,4′,6-tri-2NM neamine
at 1, 5 and 10 times MIC. Each value is the mean of two independent experimental
determinations±SEM.
1720 M. Ouberai et al. / Biochimica et Biophysica Acta 1808 (2011) 1716–1727ability of 3′,4′,6-tri-2NM neamine to inhibit the protein synthesis using
an in vitro transcription/translation assay [35]. The effects on bacterial
protein synthesis of all selected compounds were determined at an
equimolar concentration of 10 μM (molar concentration equivalent to
the MIC of the 3′,4′,6-tri-2NM neamine on P. aeruginosa ATCC 27853)
and at the MIC. As expected, we conﬁrmed the inhibitory effect of
neamine, neomycin B, gentamicin as well as chloramphenicol and
tetracycline on bacterial protein synthesis. In contrast, 3′,4′,6-tri-2NM
neamine did not inhibit protein synthesis and showed similar proﬁles as
the ones obtained with colistin, chlorhexidine, and aztreonam. Colistin
and chlorhexidin are known to act on the membrane [52,53] whereas
aztreonam interacts with the bacterial cell wall synthesis and blocks
peptidoglycan cross-linking [54]. The absence of an inhibitory effect on
the protein synthesiswas independent on the number (two or three) of
naphthylmethylene groups substituting neamine as well as the
concentrations selected (equimolar concentrations (10 μM; Fig. 2A) or
MICs against P. aeruginosa ATCC 27853 (Fig. 2B)). Even at 10-fold the
MIC, the 3′,4′,6-tri-2NM neaminewas unable to signiﬁcantly inhibit the
protein synthesis (Fig. 2C).
These results clearly showed that the addition of naphthylmethy-
lene groups to the neamine backbone changes the primary mode of
action of aminoglycosides since both the di- and tri-substituted
derivatives are unable to inhibit the protein synthesis whatever the
conditions used (10 μM or at their MICs).
3.3. Nanoscale imaging of P. aeruginosa cells
Since the 3′,4′,6-tri-2NM neamine did not affect protein synthesis,
we further investigated the effect of this compound on the surface
of P. aeruginosa ATCC 27853 using in situ AFM imaging [55,56].
Cells immobilized onto polycarbonate membranes were imaged in
aqueous solution without any pre-treatment such as air drying or
chemical ﬁxation. Fig. 3 shows deﬂection images for the same bacterium
following incubation with 3′,4′,6-tri-2NM neamine at 0.5-fold MIC.
Series of deﬂection images were recorded up to 35 min. As shown in the
vertical cross-sections, the bacterium progressively ﬂattened over the
course of the experiment. The cell thickness decreased by 50% after
33 min.We interpret such swellingdownas evidence for the alteration of
the cell wall leading to the discharge of most of the intracellular content.
Finally, after 35 min, the remaining bacteriumdetached from the surface.
3.4. P. aeruginosa membrane depolarization
To gain insights on the effect of 3′,4′,6-tri-2NM neamine on the
P. aeruginosa ATCC 27853 membrane, we investigated the ability of
this compound to depolarize the bacterial membrane using DiSC3(5),
a membrane potential-dependent probe [36]. Upon permeabilization
and disruption of the membrane, the membrane potential will be
dissipated, and DiSC3(5) will be released into the medium causing a
consequent increase in ﬂuorescence [40]. Valinomycin, a K+ ionophore
leading to depolarization of the cytoplasmic membrane was used as
positive control. At 10 μM, it increased the ﬂuorescence intensity of
DiSC3(5) more than 10-fold.
When compoundswere tested at equimolar concentration (10 μM)
(Fig. 4A), the 3′,4′,6-tri-2NM neamine induced membrane depolar-
ization but less than valinomycin (8.5-fold increase in ﬂuorescence
versus 12-fold, respectively). In contrast, the 3′,6-di 2NM neamine,
neamine and gentamicin showed no effect. Neomycin B induced a
small effect, with an increase of relative ﬂuorescence around 3.3-fold.
When the membrane depolarization was measured after addition
of compounds at their MICs (Fig. 4B), we found a clear dissipating
membranepotential effect inducedby thedi- and tri-substitutedneamine
derivatives with a 11- and 8.5-fold increase in relative ﬂuorescence,
respectively.NeomycinBandneaminealso induced, but in a lesser extent,
an increase in relative ﬂuorescence (5.7- and 3.9-fold, respectively).
In contrast, gentamicin did not induce membrane depolarization.To gain further data about the mechanism involved, we compared,
at 10 μM and at their MICs, the effect of aminoglycosides to other
antibacterial (colistin) or biocidal drugs (chlorhexidine), known to
Fig. 3. AFM imaging of single P. aeruginosa ATCC 27853 cell following incubation with 3′,4′,6-tri-2NM neamine at 0.5-fold MIC against P. aeruginosa 27853. A series of deﬂection
images (3 μm×3 μm) recorded in real time for a single cell prior and after treatment is shown. The lower panel compares vertical cross-sections.
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chlorhexidine showed a similar effect to the one observed with
3′,4′,6-tri-2NMneamine whereas at equimolar concentration (10 μM)
(Fig 4A), chlorhexidine was more effective than 3′,4′,6-tri-2NM
neamine.
Additionally, we investigated the dose-dependent effect in multi-
ples of MICs (Fig. 4C). 3′,4′,6-tri-2NM neamine induced an increase ofﬂuorescence for concentrations ranging from 0.1 to the MIC. A plateau
value was observed at 0.25-fold theMIC. The di-substituted derivative
induced a more progressive increase of the signal between 0.1- to
1-fold MIC.
All together, 3′,4′,6-tri-2NM neamine clearly induced P. aeruginosa
membrane depolarization. At equimolar concentration, 3′,6-di-2NM
neamine did not modify the membrane polarization.
Fig. 4. Effect of Neamine derivatives (3′,4′,6-tri-2NM neamine, 3′,6-di-2NM neamine),
neamine, neomycin B, gentamicin, colistin and chlorhexidine on the ﬂuorescence
intensity changes of P. aeruginosa ATCC 27853 incubated with DiSC3(5). The
experiments are performed at 10 μM (panel A) and at their MICs (see individual
values in legend of Fig. 2) against P. aeruginosa 27853 (panel B). Panel C shows the effect
of 3′,4′,6-tri-2NM neamine and 3′,6-di-2NM neamine at 0.1-, 0.25-, 0.5-, and 1-foldMIC.
Results are expressed in relative intensity ﬂuorescence observed at 670 nm as
compared to negative control. Valinomycin (10 μM) was used as positive control.
Values are mean±SD of three determinations.
Fig. 5. Binding afﬁnity of compounds to LPS determined by the BODIPY-Cadaverine
displacement method. Colistin (▪) is used as the reference compound in comparison to
the effect obtained for 3′,4′,6-tri-2NM neamine (•), 3′,6-di-2NM neamine (▲),
neamine (♦), chlorhexidine (*), imipenem (□) and meropenem (∇). Experimentsare reproduced two times with identical results.
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Since LPS is the main outer membrane constituent of Gram-
negative bacteria, we examined the ability of 3′,4′,6-tri-2NM neamine
to bind to LPS, using a ﬂuorescence based displacement assay
with BODIPY-TR-cadaverine [41] (Fig. 5). The effects of neamine,
3′,6-di-2NM neamine, colistin, chlorhexidine, imipenem and mer-
openem were monitored in parallel. Colistin (polymyxin E) showedan effect similar to the one observed with polymyxin B, a decapeptide
antibiotic, which is known to bind to LPS [40,57,58] and is generally
used as a reference compound. Penems, which bind to penicillin
binding proteins and thus prevent bacterial cell wall synthesis, did
not induce any effect. Naphtylmethyl neamine derivatives, chlorhex-
idine and neamine showed intermediate effects with the highest
potency for the 3′,4′,6-tri-2NM neamine to displace BODIPY-TR-
cadaverine from its binding to LPS, followed by the 3′,6-di-2NM
neamine, chlorhexidine and neamine. The apparent Kd values
obtained for chlorhexidine and colistin are similar to those reported
by others [59].
3.6. Lipid membrane permeabilization
Ensuing the marked effect of 3′,4′,6-tri-2NM neamine on mem-
brane properties of P. aeruginosa, especially on the membrane
thickness and the membrane polarization, we investigated the ability
of this compound to permeabilize artiﬁcial lipid membranes. This
was examined on liposomes mimicking the lipid composition of
P. aeruginosa membranes (POPE:POPG:CL; 60:21:11) [43,44]. Calcein
was entrapped within these vesicles at a self-quenching concentra-
tion. Increase of its ﬂuorescence reﬂects its dequenching due to
membrane permeabilization and release of the dye.
At 10 μM, both 3′,4′,6-tri-2NM neamine and 3′,6-di-2NM neamine
induced a marked increase in the ﬂuorescence signal which reached a
value similar to that obtained with Triton X-100 (Fig. 6A). This
permeabilizing effect was rapid since all calcein was released within
the ﬁrst 5 min (data not shown). Only around 20% of the calcein was
released by the parent compound, neamine, as well as by the clinically
used aminoglycosides, neomycin B and gentamicin.
When measured at the MIC against P. aeruginosa ATCC 27853, the
release of calcein induced by tri-substituted and di-substituted
derivatives was comparable to that of Triton X-100 and slightly
higher than that observed with neomycin B. Gentamicin did not
induce a release of calcein and neamine allowed a release of
approximately 20% of calcein (Fig. 6B).
When we compared the effect of aminoglycosides to those
obtained with colistin and chlorhexidine known to induce permea-
bilization, we observed a release of calcein which reached 100% with
chlorhexidine and around 70% with colistin, depending on the
experimental conditions (Fig. 6A and B).
For both tri-substituted and di-substituted derivatives, the effect
was clearly dose-dependent (between 0.01- and 1-fold the MIC)
(Fig. 6C). Systematically, the 3′,4′,6-tri-2NM neamine induced a
Fig. 6. Effect of neamine derivatives (3′,4′,6-tri-2NM neamine, 3′,6-di-2NM neamine),
neamine, neomycin B, gentamicin, colistin and chlorhexidine on the release of calcein
entrapped within liposomes. Liposomes (5 μM phospholipids) made of POPE:POPG:CL
(60:21:11 molar ratio) are exposed with compound at 10 μM (panel A) or at their MICs
(see individual values in legend of Fig. 2) (panel B) for 1 h at 37 °C. Panel C shows the
effect of 3′,4′,6-tri-2NM neamine at 0.01-, 0.025-, 0.05-, 0.1-, 0.25-, 0.5- and 1-fold MIC
against P. aeruginosa 27853. The ordinate shows the maximal percentage of calcein
released compared to what was observed after addition of 2% Triton X-100. Each value
is the mean of two independent experimental determinations±SD.
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3′,6-di-2NM neamine. For both compounds, the maximal effect was
obtained at 0.05-fold the MIC.
These studies therefore suggested that on artiﬁcial membranes,
both the di- and the tri-substituted derivatives induced a lipid
membrane permeabilization at equimolar concentrations as well as at
their MICs and even at very low concentrations.3.7. Interactions with polar heads and interfacial domains of
phospholipids
To further characterize the 3′,4′,6-tri-2NM neamine and 3′,6-di-
2NM neamine binding to lipids, we calculated the lipid insertion
propensity of both compounds by molecular modeling using neamine
and neomycin B as reference compounds. The Impala plot (Fig. 7)
showed that neamine (Fig. 7A) and neomycin B (Fig. 7B) were located
near or on the polar head group/water interface, while 3′,6-di-2NM
neamine (Fig. 7C) and 3′,4′,6-tri-2NM neamine (Fig. 7D) inserted
more deeply into the modeled membrane. The deepest carbon atom
of the di-substituted neamine derivative was at the level of the
acyl-chain C4–C5 atom while this was located at the C9 level for the
tri-substituted derivative. This correlated with the calculation of
the ratio of the hydrophobic (pho)/hydrophilic (phi) surface and of
the transfer energy (Table 2), showing that the two amphiplilic
derivatives are more hydrophobic than the controls.
The interaction with lipids mimicking those found in membranes
of P. aeruginosa [phosphatidylethanolamine (POPE), phosphatidylgly-
cerol (POPG) or cardiolipin (CL)] was further investigated for the two
neamine derivatives and compared to the interaction of neomycin
B. Neamine was not further considered since its interaction with the
model membrane was less signiﬁcant (Fig. 7) in accordance with the
inability of this compound to alter bacterial membranes and/or to
reach intracellular bacterial targets. The interaction between the
drugs and POPE is shown in the Supplementary Material. Again, the
interaction of the neamine derivatives occurred at the interface
between the polar head groups and the acyl chains of the lipid (panels
B and C) with a deeper insertion of 3′,4′,6-tri-2NM neamine (panel C),
while neomycin B interacted with the head groups (panel A). Hence,
the interaction energy of the whole complex further suggested that
the interaction was stabilized by hydrophobic and Van der Waals
energies for the neamine derivatives. Taking into account the three
positive charges of aminoglycosides, we also determined their
interaction with negatively charged lipids like cardiolipin. The
contribution of electrostatic energies was the most important for
neomycin B, in agreement with its relative membrane location at
the phospholipid head group/water interface. This contribution
decreased for the di-substituted derivative and even more for the
tri-substituted neamine which is in accordance with their deeper
insertions in the bilayer. The same was observed when the interaction
of the di-substituted derivative with POPG – another negatively
charged lipid – as compared to that of the tri-substituted one. In
contrast, no major differences in the contribution of electrostatic
energies could be found when the di- and tri-derivatives were
interacting with POPE, a zwitterionic phospholipid (Table 3).
4. Discussion
Aminoglycosides are highly potent, broad-spectrum antibiotics
with many desirable properties for the treatment of life-threatening
infections. However, despite rigorous patient monitoring, nephro-
and oto-toxicities appear as relatively frequent side effects of
therapeutic courses [60–62]. Aminoglycosides act by binding to 16S
rRNA, causing mRNA decoding errors, mRNA and tRNA translocation
blockage, ribosome recycling inhibition and in ﬁne protein synthesis
alteration [14]. The emergence of resistant strains has somewhat
reduced the potential of these antibacterials leading to treatment
failure. In the search for new antimicrobial agents and/or new targets,
we introduced hydrophobic groups, like arylmethylene groups, on the
neamine backbone [23]. Of the sixteen mono-, di-, tri- and tetra-aryl
methylene neamine derivatives synthesized, the 3′,4′,6-tri-2-
naphthylmethylene neamine (3′,4′,6-tri-2NM neamine) showed a
very interesting activity against both Gram-positive and Gram-
negative strains. Even if the 3′,4′,6-tri-2NM neamine does not reach
the high activity of conventional aminglycosides like gentamicin
Fig. 7. Interaction of neamine (A), neomycin B (B), 3′,6-di-2NM neamine (C) and 3′,4′,6-tri-2NM neamine (D) with the IMPALA membrane Yellow plane=bilayer center (z=0);
mauve plane=lipid acyl chain/polar head group interface at (z=13.5 Å from the center); pink plane=lipid/water interface (z=18 Å).
Table 3
Calculation of the interaction energy for the complexes presented on Fig. 8.
Molecule ETot
(kcal/mol)
Epho–EVDW
(kcal/mol)
Eelec
(kcal/mol)
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spectrum of activity against resistant strains including bacteria expres-
sing enzymes inactivating aminoglycosides as well as against strains
expressing rRNAmethylases or S. aureusMRSA, VRSA [23]. Interestingly,
and as also reported for amphiphilic aminoglycoside-peptide triazole
conjugates [63], the 3′,4′,6-tri-2NMneamine exhibited higher or similar
activity against P. aeruginosa, E. coli and S. aureus – resistant strains as
compared to sensitive strains. The ﬁrst studies examining the binding
of these naphtylmethylene derivatives to amodel of bacterial ribosomal
A site by microcalorimetry or quantifying the protein synthesis by
measuring leucine incorporation [23], suggested a major shift in the
primary mode of action of these aminoglycosides.
In this work, by using an in vitro transcription/translation assay
[35], we conﬁrmed that 3′,4′,6-tri-2NM neamine failed to inhibit the
bacterial protein synthesis. This could eventually be caused by the
steric hindrance of the naphthylmethylene groups resulting in a
decrease of RNA site A recognition [23]. A similar assumption has been
drawn by Zhang and collaborators, who synthesized neomycin
derivatives bearing linear lipidic acyl groups with various chain
lengths (from C7 to C18) at the 5″ position [19].Table 2
Calculation of the ratios of the hydrophobic (pho) and hydrophilic (phi) surfaces
(S; calculated as in Ref. [84]) and energies (Etr) of the 3′,6-di-2NM neamine, 3′,4′,6-tri-
2NM neamine, neamine and neomycin B.
Molecule Spho/Sphi Etr pho/Etrphi
Neamine 0.4 0.25
Neomycin B 0.5 0.35
3′,6-di-2NM neamine 2.3 1.4
3′,4′,6-tri-2NM neamine 3.5 2.3Because the 3′,4′,6-tri-2NM neamine has shown a very interesting
antibacterial effect on Gram-negative bacteria despite its inability to
inhibit the protein synthesis, we investigated the mechanism
involved. One of the most likely hypotheses could be that the addition
of hydrophobic groups on the aminoglycoside backbone alters the
mode of action from an intracellular to a membraneous target. To
explore this hypothesis, we characterized the effect of 3′,4′,6-tri-2NM
neamine on the entire bacteria at the nanoscale using AFM, and on the
membrane depolarization using DiSC3(5) assay. In parallel, we
investigated the ability of 3′,4′,6-tri-2NM neamine to bind to LPS,
the main component of the external membrane of Gram-negative
bacteria, and to permeabilize lipid membranes. We showed that
3′,4′,6-tri-2NM neamine induced a decrease of the thickness ofNeomycin B/CL −238 −96 −142
Neomycin B/POPE −184 −70 −114
Neomycin B/POPG −240 −120 −120
3′,6-di-2NM neamine/CL −196 −116 −80
3′,6-di-2NM neamine/POPE −277 −150 −127
3′,6-di-2NM neamine/POPG −315 −175 −140
3′,4′,6-tri-2NM neamine/CL −165 −160 −5
3′,4′,6-tri-2NM neamine/POPE −283 −156 −127
3′,4′,6-tri-2NM neamine/POPG −204 −134 −72
ETot=total energy (sum of Epho-VDW and Eelec); Epho: hydrophobic energy, EVDW: van
der Waals energy, Eelec: electrostatic energy. CL: Beef heart cardiolipin, POPG: 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol), POPE:1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoethanol-amine.
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It also bound to LPS and induced membrane permeabilization.
The importance of each of these alterations for antibacterial activity
is still unclear even if for cholic acid-derived antimicrobial agents,
membrane depolarization seems play a critical role [64]. Regarding
AFM results, further experiments will be necessary to understand the
role played by the decrease of the height of bacterial wall for bacterial
death since our pictures by AFM did not show the appearance of holes
as it was the case with lipoglycopeptides [65]. All together, results
indicated that naphthylmethyl neamine derivatives target the
membrane of P. aeruginosa. They are in accordance with molecular
modeling, an approach previously validated by the experimental data
obtained with peptides known to interact with membranes [66,67]
and which allowed to predict the insertion of tilted peptide [68], to
design de novo a fusogenic peptide made of non-natural amino acids
[69] and to conﬁrm experimental data related to drug/lipid interac-
tions (e.g., [70]). In this study, calculations showed that 3′,4′,6-tri-
2NM neamine was inserted deeply into the modeled membrane and
was prone to interact strongly with lipids present in Pseudomonas
membranes.
Comparing the di- (3′,6-di-2NM neamine) and the tri- (3′,4′,6-tri-
2NM neamine) substituted derivatives, at equimolar concentration
(10 μM), only the tri-substituted derivative is able to depolarize
P. aeruginosa membrane. Moreover, using Bodipy cadaverine ﬂuores-
cent probe displacement, the tri-substituted neamine derivative
was 13-fold more effective to interact with LPS as compared
with the di-substituted neamine derivative. This could be related
to the microbiological effects which showed that only the tri-
substituted derivative was active against Gram-negative bacteria.
The tri-substituted derivative probably inserted more deeply into
adjacent LPS molecules and acted as a spacer in the plane of the
bilayer, reducing the short-range attractive forces between LPS
saccharide cores and inducing release of LPS. This has previously
been described for biosurfactants like rhamnolipids, which solubilize
hydrophobic compounds within micellar structures and cause the cell
surface of P. aeruginosa to become more hydrophobic through release
of LPS [71].
At a glance, the effect of the 3′,4′,6-tri-2NM neamine could
therefore be due to the release of LPS, the accumulation of the
compound within the membrane and the subsequent destabilization
of the lipid membrane. Electrostatic interactions are probably critical
at the initial stage of bacterial recognition. The positive charges of the
amphiphilic aminoglycosides conceivably target the anionic environ-
ment of Gram-negative bacteria due to the anionic bisphosphorylated
sugar head groups of LPS as well as the negatively charged lipids like
cardiolipin and POPG. These results are in agreement with our
molecular modeling and the values of energy. Our data are also in
accordance with the model designed for dicationic linear molecules
interacting with LPS. This model hypothesized distances between
charged amino groups inter NH2 distances from 5 to 16 Å allowing
interactions with the negatively charged phosphates of lipid A [72]
and decrease of the area per hydrocarbon chain of LPS [73]. Our
calculations suggested a maximum distance of 8.5 Å between the
furthest cationic amino functions of 3′,4′,6-tri-2NM neamine. The
hydrophobic interaction between the amphiphilic aminoglycosides
and LPS could play an additional critical role for the speciﬁcity and
antibacterial activity. This correlates with the hydrophobic/hydro-
philic balance of 3′,4′,6-tri-2NM neamine and 3′,6-di-2NM neamine
as shown by their log P/log D. The calculated log P and log D (at pH 7)
of 3′,4′,6-tri-2NM-neamine and 3′,6-di-2NM neamine are −9.3 and
−0.4, and −12.7 and −4.1, respectively. These differences in
interactions with phospholipids between the di- and tri-substituted
neamines could explain the decrease of the contribution of electro-
static energies for 3′,4′,6-tri-2NM neamine in interaction with
negatively charged lipids like cardiolipine or POPG in comparison of
the energies found for 3′,6-di-2NM neamine.Regarding the interactions with lipidmembranes as well as on LPS,
the tri-naphthylmethylene neamine derivative seems to act on lipid
bacterial membranes as do polymyxins like colistin. Polymyxins are
polycationic peptides with D- and L-amino acids in a cyclic heptapep-
tide ring carrying a tripeptide chain and a fatty acid chain. Colistin
(polymyxin E) is distinguished from polymyxin B through the
replacement of D-phenylalanine by D-leucine in the polypeptide ring
[25–29,74,75]. In addition to thewell-known binding to LPS, colistin is
able to interact with lipid membranes by inducing molecular contacts
between the inner and outer membranes of the bacteria resulting
in lipid exchange, unequal pressure forces, rearrangement to the
inner membrane and formation of a transient hole in the membrane
[25–29]. As compared to the requirement of the naphthyl groups to
observe membraneous effect and binding to LPS for amphiphilic
aminoglycosides, the role of the lipophilic tail is critical since
treatment of polymyxins with ﬁcin or related enzymes that remove
the lipid moiety (the 6-methyoctanoyl or 6-methylheptanoylresidue)
induced a loss of antibacterial activity [76].
The biological relevance of this study is another important question
to answer. Considering the drug/lipid ratio, the molecular modeling
suggested that onemolecule of drug is surrounded by 6 to 8molecules
of lipids, depending on the lipid type, a ratio close to that previously
reported for kanamycin, gentamicin and slightly lower than that
reported for antimicrobial peptides [77]. In MIC experiments, about
105 bacteria are present in 1 ml ofmedia and the accepted approximate
number of lipids per cell is 2.2×107 to 2.5×107. These values lead to a
total lipid concentration of 3.65×10−3 μmol/l. Considering the MIC of
the 3′,4′,6-tri-2NM neamine is around 4 μg/ml, this translates to a
surprisingly high drug/lipid ratio of 1/0.001 at this concentration. Even
if the cell density is 107 to 109 per ml, the drug/lipid ratio is still high.
This calculation suggests that in the biophysical studies with model
membranes the drug/lipid ratio used is drastically below of a standard
MIC experiment. Therefore, the drug/lipid ratios used in biophysical
assays are extremely conservative, in that very small drug concentra-
tions (far below the MIC) can cause signiﬁcant membrane perturba-
tion. Thus, it is likely that the perturbation occurring at these low drug/
lipid ratios will also occur at the MIC [78]. Considering the time-frame
of the cellular alterations (bacterial death, membrane depolarization
and permeabilization), we cannot extrapolated from the present data.
In addition, literature suggested that drug-induced loss of viability is
not simply a consequence of membrane depolarization [79].
Finally, the potential interaction withmammalianmembranes and
the potential cell toxicity remain to be evaluated. The concept of a
characteristic lipid composition for a given cell membrane is well
accepted, although changes in lipid compositionmay occur depending
on environmental conditions [80,81]. One feature that distinguishes
the membranes of prokaryotic organisms from those of eukaryotic
organisms is that the former harbor more negatively charged lipids in
the outer leaﬂet of the plasma membrane. Most Gram-negative
bacteria contain~25% of negatively charged lipids such as phospha-
tidylglycerol or cardiolipin and~75% of phosphatidylethanolamine as
their most common zwitterionic lipid. In contrast, the outer leaﬂet of
the asymmetric eukaryotic cells, the erythrocyte membrane bilayer is
devoid of anionic lipids and composed of ~25% cholesterol, ~33%
phosphatidylcholine, ~18% sphingomyelin, and ~9% phosphatidyleth-
anolamine. On the premise that the composition of membrane
phospholipids differs between the microbial and human cells, design
of new amphiphilic neamine derivatives should take into account
these differences to improve the selectivity for the targeted bacterial
membranes.
In this respect, the number and position of the substituents as well
as the hydrophilic/hydrophobic balance of the synthesized derivatives
have to be carefully designed. We showed here that limited
modiﬁcations in the structure of the neamine derivatives, i.e., the
addition of one naphthyl ring from the di-substituted derivative,
allows to target Gram-negative bacteria even if the number and the
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groups in the di-2NM derivatives is also critical since the 3′,4′-di-2NM
neamine and 3′,6-di-2NM neamine are much more efﬁcient against S.
aureus (ATCC 25923) than the 4′,5-di-2NM neamine and 4′,6-di-2NM
neamine. Yet, the 3′,4′,6-tri-2-quinolylmethylene neamine derivative
(3′,4′,6-tri-2QN) which differs from the 3′,4′,6-tri-2NM derivative
through the simple replacement in each naphthyl rings of one carbon
by a nitrogen atom, is inefﬁcient against Gram(+) and Gram(−)
bacteria [23], suggesting that minor structural changes can have large
consequences on the biological effects.
In a nutshell, this work showed that the introduction of
naphthylmethylene groups on the neamine backbone shifts the
mechanism of action from an intracellular target mechanism to a
membrane target effect. Such a target is particularly desirable since it
is unlikely to be susceptible to existing mechanisms of bacterial
resistance. Relation–structure activity studies should be very helpful
to select and design derivatives with appropriate hydrophobic/
hydrophilic balance as well as a steric hindrance to improve the
selectivity for bacterial membranes and LPS or to target both
ribosomal RNAs and lipid membranes. Such strategy has successfully
been followed for lipoglycopeptides like telavancin and oritavancin
[65,82] and is now in progress for aminoglycosides.
In conclusion, this work suggests that amphiphilic neamine
derivatives are attractive targets for drug development. This can be
extended to other cationic amphiphiles inspired by the natural
antimicrobial scaffold [83]. However, before the usefulness of the
drug in clinical settings, extensive relation–structure activity studies,
work to overcome potential pharmacokinetic shortcomings including
formulation difﬁculties and assessment of preclinical toxicity studies
remain to be established.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2011.01.014.
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